Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2023 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled Trial.
Lederman S, Arnold LM, Vaughn B, Kelley M, Sullivan GM. Lederman S, et al. Arthritis Care Res (Hoboken). 2023 Nov;75(11):2359-2368. doi: 10.1002/acr.25142. Epub 2023 Jul 4. Arthritis Care Res (Hoboken). 2023. PMID: 37165930 Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of TNX-102 SL, a once-nightly sublingual formulation of cyclobenzaprine, in reducing pain in patients with fibromyalgia (FM). METHODS: RELIEF was a double-blind, randomized, placebo-controlled trial. ...Secondary end points in …
OBJECTIVE: To evaluate the efficacy and safety of TNX-102 SL, a once-nightly sublingual formulation of cyclobenzaprine, in reducing p …
Cyclobenzaprine-related adverse events: a comprehensive pharmacovigilance analysis using the FDA Adverse Event Reporting System.
Tu J, Zhang C, Xie S, He J, Zhang H. Tu J, et al. Front Med (Lausanne). 2025 Sep 22;12:1574395. doi: 10.3389/fmed.2025.1574395. eCollection 2025. Front Med (Lausanne). 2025. PMID: 41058614 Free PMC article.
BACKGROUND: Cyclobenzaprine, a centrally-acting muscle relaxant, is widely used for the treatment of musculoskeletal pain. ...Furthermore, the Weibull distribution was utilized to construct a model for the risk of adverse events as time progresses. RESULTS: Out of 18,289,3 …
BACKGROUND: Cyclobenzaprine, a centrally-acting muscle relaxant, is widely used for the treatment of musculoskeletal pain. ...Further …
Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study.
Darwish M, Xie F. Darwish M, et al. Drugs Aging. 2009;26(2):95-101. doi: 10.2165/0002512-200926020-00001. Drugs Aging. 2009. PMID: 19220066 Clinical Trial.
Outcome measures included area under the plasma cyclobenzaprine concentration versus time curve (AUC) to 168 hours (AUC168) and infinity (AUC infinity), peak plasma cyclobenzaprine concentration (Cmax), time to observed Cmax (tmax) and terminal elimination half-life …
Outcome measures included area under the plasma cyclobenzaprine concentration versus time curve (AUC) to 168 hours (AUC168) and infin …
Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study.
Darwish M, Hellriegel ET, Xie F. Darwish M, et al. Clin Drug Investig. 2008;28(12):793-801. doi: 10.2165/0044011-200828120-00007. Clin Drug Investig. 2008. PMID: 18991473 Clinical Trial.
Measures included area under the plasma cyclobenzaprine concentration versus time curve (AUC) to 168 hours and infinity, maximum plasma cyclobenzaprine concentration (C(max)), and time to observed C(max) (t(max)). ...All AEs were mild in intensity; the most common …
Measures included area under the plasma cyclobenzaprine concentration versus time curve (AUC) to 168 hours and infinity, maximum plas …
Efficacy and tolerability of cyclobenzaprine extended release for acute muscle spasm: a pooled analysis.
Weil AJ, Ruoff GE, Nalamachu S, Altman CA, Xie F, Taylor DR. Weil AJ, et al. Postgrad Med. 2010 Jul;122(4):158-69. doi: 10.3810/pgm.2010.07.2182. Postgrad Med. 2010. PMID: 20675978 Clinical Trial.
OBJECTIVE: To assess the efficacy and tolerability of once-daily cyclobenzaprine extended release (CER) 15 and 30 mg in relieving acute muscle spasm. METHODS: This is a pooled analysis of 2 randomized, double-blind, placebo-controlled, parallel-group studies of identical d …
OBJECTIVE: To assess the efficacy and tolerability of once-daily cyclobenzaprine extended release (CER) 15 and 30 mg in relieving acu …